Online inquiry

IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3184MR)

This product GTTS-WQ3184MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANPEP gene. The antibody can be applied in Mesothelioma, Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001150.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 290
UniProt ID P15144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3184MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11705MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ1725MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ3542MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ2815MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ8141MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ406MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ6857MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ8176MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW